3 ms·

> universal healthcare The US spends more, per captia on socialized medicine than Germany. Why do we need to spend even more?

rayiner 3y ago
Because Americans don’t want a healthcare system that tells grandma they’re too old for expensive surgery.
- willcipriano 3y ago
  If it was too expensive the time to say something isn't after a lifetime of cashing insurance premium checks.
- chiefalchemist 3y ago
  We also don't want a healthcare system that focuses on prevention. A significant percentage of what the USA spends on healthcare could be mitigated with prevention. But there's no profit in prevention, and the general population doesn't want to sacrifice comfort and convenience. "What do you mean change my diet and lifestyle??"
  - willcipriano 3y ago
    Obesity is 8% higher in the US than the UK. The NHS costs half as much per captia as medicare, medicaid, etc and provides universal coverage. That isn't it. It's simply theft.
  - skissane 3y ago
    > But there's no profit in prevention Drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are making massive profits, and also have decent odds of preventing many obesity-induced (and also diabetes-induced) diseases Okay, they also have side effects, and it is possible the disease burden caused by the side effects may (in the long-run) turn out to be worse than the disease burden they prevent. But, while that's a possibility, it is only a possibility, a possibility which could easily not come pass to And even if some of those drugs turn out to have unacceptable side effects in the long-run, there are other drugs in that class in the pipeline which might avoid those side effects, in which case the profits will shift to those
    - JamesBarney 3y ago
      > Okay, they also have side effects, and it is possible the disease burden caused by the side effects may (in the long-run) turn out to be worse than the disease burden they prevent. But, while that's a possibility, it is only a possibility, a possibility which could easily not come pass to This is very unlikely to happen. This isn't like other obesity drugs that were first in class, glp-1 agonists have been around a long time and have a great safety record.

rayiner 3y ago

Because Americans don’t want a healthcare system that tells grandma they’re too old for expensive surgery.

willcipriano 3y ago
If it was too expensive the time to say something isn't after a lifetime of cashing insurance premium checks.
chiefalchemist 3y ago
We also don't want a healthcare system that focuses on prevention. A significant percentage of what the USA spends on healthcare could be mitigated with prevention. But there's no profit in prevention, and the general population doesn't want to sacrifice comfort and convenience. "What do you mean change my diet and lifestyle??"
- willcipriano 3y ago
  Obesity is 8% higher in the US than the UK. The NHS costs half as much per captia as medicare, medicaid, etc and provides universal coverage. That isn't it. It's simply theft.
- skissane 3y ago
  > But there's no profit in prevention Drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are making massive profits, and also have decent odds of preventing many obesity-induced (and also diabetes-induced) diseases Okay, they also have side effects, and it is possible the disease burden caused by the side effects may (in the long-run) turn out to be worse than the disease burden they prevent. But, while that's a possibility, it is only a possibility, a possibility which could easily not come pass to And even if some of those drugs turn out to have unacceptable side effects in the long-run, there are other drugs in that class in the pipeline which might avoid those side effects, in which case the profits will shift to those
  - JamesBarney 3y ago
    > Okay, they also have side effects, and it is possible the disease burden caused by the side effects may (in the long-run) turn out to be worse than the disease burden they prevent. But, while that's a possibility, it is only a possibility, a possibility which could easily not come pass to This is very unlikely to happen. This isn't like other obesity drugs that were first in class, glp-1 agonists have been around a long time and have a great safety record.